Literature DB >> 25556715

Treatment of multidrug-resistant pseudomonas aeruginosa using extended-infusion antimicrobial regimens.

Emily L Heil1, Ashleigh V Lowery, Kerri A Thom, David P Nicolau.   

Abstract

In the management of multidrug-resistant infections in critically ill patients with multiorgan dysfunction, consideration must be given to the pharmacokinetics and pharmacodynamics of an antimicrobial agent to optimize dosing. We describe a 25-year-old woman who was undergoing thrice-weekly hemodialysis and developed multidrug-resistant Pseudomonas aeruginosa bacteremia secondary to infected left and right ventricular assist devices. After multiple courses of antibiotics, her blood cultures revealed that the infecting organism was becoming progressively more resistant to antibiotic options. Cefepime 2 g administered over 3 hours/day (in combination with colistimethate) provided adequate drug levels for multidrug-resistant, cefepime-intermediate P. aeruginosa bacteremia in this patient. We present the clinical case of this patient, followed by a discussion of possible therapeutic approaches to be considered, including illustration of the principles of using extended-infusion antimicrobial regimens, and present the patient's resulting clinical course.
© 2014 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  Pseudomonas; cefepime; multidrug-resistant

Mesh:

Substances:

Year:  2014        PMID: 25556715     DOI: 10.1002/phar.1514

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  2 in total

1.  Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.

Authors:  Wesley D Oliver; Emily L Heil; Jeffrey P Gonzales; Shailly Mehrotra; Kathryn Robinett; Paul Saleeb; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

Review 2.  Clinical pharmacology considerations for children supported with ventricular assist devices.

Authors:  Jennifer Sherwin; Elizabeth Thompson; Kevin D Hill; Kevin Watt; Andrew J Lodge; Daniel Gonzalez; Christoph P Hornik
Journal:  Cardiol Young       Date:  2018-07-11       Impact factor: 1.093

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.